Plain-English translation of NCT02974647 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Lymphoma research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a medication called for patients with T or NK cell lymphomas that have not responded to previous treatments or have come back after treatment. works by blocking proteins that help these cancer cells survive and grow. The medication may help shrink the lymphoma by stopping these proteins from working.
Many patients with T or NK cell lymphomas find that standard treatments stop working or the cancer comes back. This trial exists to see if this medication could offer hope to patients whose options are limited, by attacking the cancer in a new way.
You likely qualify if…
You likely don't qualify if…
You would take the medication by mouth twice a day, roughly 12 hours apart, in 28-day cycles. You would continue taking it as long as it is helping your lymphoma shrink and you are tolerating it well. Throughout the trial, you would have regular visits with the study team to check how you are doing, including blood tests and scans to see if the lymphoma is responding to treatment.
AI-generated summary from trial data · Aug 5, 2026 · Not medical advice
United States